Oral Squamous Cell Carcinoma Presenting in a Patient Receiving Adalimumab for Rheumatoid Arthritis

The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh et al. · Arthritis & Rheumatism · 2005 · 1.8K citations

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Daniel E. Fürst, Edward Keystone, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2011 · 691 citations

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

P. Geborek · Annals of the Rheumatic Diseases · 2005 · 429 citations · Full text

The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observation

Frederick Wolfe, Kaleb Michaud · Arthritis & Rheumatism · 2007 · 346 citations

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

Frances Rena Bahjat, Polly Pine, Andrea Reitsma et al. · Arthritis & Rheumatism · 2008 · 172 citations